The companies involved are Revivicor, the Blacksburg xenotransplantation company behind a pig-to-human heart transplantation in 2022, and United Therapeutics, a Maryland biotechnology company that owns Revivicor.
The companies involved are Revivicor, the Blacksburg xenotransplantation company behind a pig-to-human heart transplantation in 2022, and United Therapeutics, a Maryland biotechnology company that owns Revivicor.
The antibody-drug conjugate trastuzumab deruxtecan continues to show impressive progression-free and overall survival gains in previously treated unresectable and/or metastatic HER2+ breast cancer.